Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O

J Clin Microbiol. 2002 Nov;40(11):4313-6. doi: 10.1128/JCM.40.11.4313-4316.2002.

Abstract

A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long exposure to these drugs with respect to baseline. The emergence of PI resistance corresponded to the selection of amino acid changes L10V, G48M, F53L, I54V, and L90M at the protease. The results were concordant with those obtained by a drug susceptibility assay with primary HIV isolates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Sequence
  • Bacteriophage lambda / drug effects
  • Bacteriophage lambda / genetics
  • Drug Resistance, Viral*
  • Female
  • HIV Protease / drug effects
  • HIV Protease / genetics
  • HIV Protease Inhibitors / pharmacology*
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • Humans
  • Indinavir / pharmacology*
  • Male
  • Microbial Sensitivity Tests / methods
  • Molecular Sequence Data
  • Phenotype
  • Saquinavir / pharmacology*
  • Time Factors

Substances

  • HIV Protease Inhibitors
  • Indinavir
  • HIV Protease
  • Saquinavir

Associated data

  • GENBANK/AF469050
  • GENBANK/AF469051
  • GENBANK/AF469052
  • GENBANK/AF469053
  • GENBANK/AF469054